secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cyclerion Therapeutics, Inc. (CYCN)
CIK:        0001755237
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0000950170-22-016016
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyclerion reports Q2 net loss $13.4M; positive CY6463 data in MELAS and CIAS studies
--------------------------------------------------------------------------------

- Cash $30.3M at June 30, 2022; net loss $13.4M vs $16.2M year ago.
- CY6463 showed improvements in biomarkers, cognitive performance, safety in MELAS and CIAS studies.
- Appointed Steven E. Hyman, M.D. to Board of Directors effective July 25, 2022.
- Enrollment ongoing in Phase 2a Alzheimer's disease with vascular pathology study; topline results expected 2023.
- R&D expenses $10.2M, G&A $3.5M; both down YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1755237/000095017022016016/0000950170-22-016016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1755237/000095017022016016/cycn-20220809.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-016016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer